PAK4 and neoplasm: Here, we used an immunocompromised SCID model to dissect immune-independent isoform-specific effects of PAK1 vs. PAK4 on tumour vasculature and gemcitabine response—focusing on tumour and vascular mechanisms without the interference of immune system effects.